Executive Vice President and Chief Technology Officer · Seres Therapeutics, Inc. (MCRB)

David Ege

FY2020 is the first fiscal year CompBrief holds for David Ege as a named executive officer of Seres Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$5,318,587

Salary $76,923Stock awards $0Bonus $65,000

1st of 3 named executive officers at Seres Therapeutics by FY2020 total.

3 named officers on file for Seres Therapeutics, FY2020

David Ege’s pay file — $29

  • 1 fiscal year of pay, line by line
  • MCRB’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Seres Therapeutics’s whole pay program stands against its peers

  • Seres Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MCRB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A).

Free

Get David Ege’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

David Ege compensation by year

Seres Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Seres Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$76,923
Bonus$65,000
Stock awards$0
Option awards$5,175,880
Non-equity incentive$0
Pension and deferred compensation$0
All other$785
Total$5,318,587

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Seres Therapeutics, Inc. DEF 14A filed April 30, 2021, accession 0001193125-21-144988, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Seres Therapeutics, Inc. filed document, accession 0001193125-21-144988. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option200,000—$32.60

Per the Outstanding Equity Awards at Fiscal Year-End table in Seres Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Seres Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
David Ege · this pageExecutive Vice President and Chief Technology Officer$5,318,587
Eric ShaffPresident and Chief Executive Officer$3,135,900
Thomas DesRosierExecutive Vice President, Chief Legal Officer and Secretary$1,437,260

The full Seres Therapeutics compensation record

free company brief

This page is one person within Seres Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Seres Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Ege's compensation dossier · One-time report. No refunds.